A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
← catalyst calendarSponsored by Agios Pharmaceuticals, Inc. (industry) · AGIO — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
87actual
Sites
45
Countries
Australia, Austria, Czechia +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-07 | actual | When the study began enrolling |
| Primary completion | 2026-03-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myelodysplastic Syndromes
Intervention
- Drug: Tebapivat — also filed as AG-946
Primary outcomes
what the primary-completion date above is the date OFPhase 2a: Proportion of Participants With Hemoglobin (Hb) Response
measured Baseline, Week 8 through Week 16
Phase 2a: Proportion of Participants With Transfusion Independence During the Core Period
measured Up to 16 weeks
Phase 2b: Proportion of Participants With Transfusion Independence
measured Up to 24 weeks
Permalink · AGIO's whole pipeline · Catalyst calendar · Every registered study · What changed